Sodium pentosan polysulfate efficacy as thromboprophylaxis agent in high‐risk women following gynecological surgery. Issue 8 (29th May 2018)

• Record Type: Journal Article
• Authors: Indirayani, Ima; Kalok, Aida; Nik Ismail, Nik A.; Shah, Shamsul A.; Lim, Pei S.; Mohamed Ismail, Nor A.; Nur Azurah, Abdul G.; Omar, Mohd Hashim; Shafiee, Mohamad N.
• Is Part Of: Journal of obstetrics and gynaecology research. Volume 44:Issue 8(2018)
• Page Start: 1458
• Page End: 1465
• Publication Date: 2018-05-29
• Subjects: embolism -- enoxaparin -- fondaparinux -- pentosan -- thrombosis; Gynecology -- Periodicals; Obstetrics -- Periodicals; 618.1005
• DOI: 10.1111/jog.13686
• Languages: English
• ISSNs: 1341-8076

Abstract

Abstract: Aim: Sodium pentosan polysulfate (Na‐PPS) is a plant‐based agent that has similar action with low‐molecular‐weight heparin. It inhibits factor Xa, preventing blood clot formation. To date, its use in clinical practice as thromboprophylaxis agent is still limited. In addition, the efficacy and safety profile of this agent was not robustly reported globally, especially for countries with major Muslim population. We hypothesized that Na‐PPS was equally effective as the standard thromboprophylaxis. We aim to compare the efficacy and safety of Na‐PPS against standard agent (fondaparinux or enoxaparin). Methods: This was a randomized control, open‐label trial. Women underwent major gynecological surgery were randomized to receive either subcutaneous 50 mg of Na‐PPS twice daily or subcutaneous enoxaparin 40 mg once daily. Fondaparinux 2.5 mg once daily was given to Muslim women as an alternative to enoxaparin. The treatment was started 6 h postoperatively, for at least 3 days. All the patients received thromboembolic deterrent stockings. The primary efficacy outcome was venous thromboembolism up to 3 days postsurgery. The main safety outcomes were minor and major bleeding. Results: Among 109 participants, there was no incidence of venous thromboembolism. None of the women developed major bleeding. Minor bleeding was observed in 28.3% (15/53) and 5.4% (3/56) of Na‐PPS and standard thromboprophylaxis group, respectively ( P = 0.001). Conclusion: Na‐PPS was associated with increased risk of minor bleeding. There was insufficient data to conclude its efficacy as thromboprophylaxis. Further research is needed to evaluate Na‐PPS safety as a standard thromboprophylactic agent.